Medicine & Life Sciences
Biological Therapy
18%
Biomarkers
10%
Cetuximab
20%
Clinical Trials
31%
Epithelial-Mesenchymal Transition
16%
ErbB Receptors
30%
Erlotinib Hydrochloride
20%
Gefitinib
20%
Genetic Therapy
14%
Head
58%
Head and Neck Neoplasms
80%
Hypoxia-Inducible Factor 1
20%
Immunotherapy
14%
Monoclonal Antibodies
11%
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
25%
Neoplasms
5%
Patents
38%
Patient Selection
14%
Phosphatidylinositol 3-Kinases
15%
Protein-Tyrosine Kinases
14%
Radiation
12%
Somatomedins
17%
Squamous Cell Neoplasms
100%
Survival
17%
Therapeutics
13%
Transferases
16%
Vascular Endothelial Growth Factor Receptor
19%
Chemical Compounds
Antagonist
37%
Antiangiogenic
55%
Antineoplastic Agent
35%
Biological Marker
36%
Erlotinib
63%
Gefitinib
63%
Resistance
25%
Transferase Inhibitor
66%
Tyrosine Kinase Inhibitor
56%
Vandetanib
76%